DocumentRX-8316
Issued
Read4 min

Marrow Therapeutics raises $173M for bone marrow-targeted therapies

Marrow Therapeutics has raised $173 million for transferrin-receptor drug delivery into bone marrow. Its MAR-101 program targets sickle cell disease and beta thalassemia.

TAG K-2175 · 815 words on the filing

Marrow Therapeutics Unveils $173M for ‘Trojan Horse’ Delivery of Blood Disorder Drugs
Marrow Therapeutics Unveils $173M for ‘Trojan Horse’ Delivery of Blood Disorder DrugsVector8DIY / pixabay

Summary of findings

  • Marrow has raised $173 million to date, including a $120 million Series B led by OrbiMed.
  • The $53 million Series A followed 2024 incubation and was co-led by Scion and venBio.
  • MAR-101 delivers siRNA to bone marrow to lower BCL11a for sickle cell disease and beta thalassemia.
  • Monkey studies showed marrow target engagement, BCL11a knockdown and potent fetal-hemoglobin induction.
  • MAR-101 remains in late preclinical testing for a possible FDA clinical-trial application, with no timeline disclosed.

By Grace Kim

Marrow Therapeutics has raised $173 million to date for a bone-marrow drug-delivery platform, led by MAR-101 for sickle cell disease and beta thalassemia. The Watertown, Massachusetts, startup unveiled its science and financing Tuesday after nearly three years of quiet development.

How does Marrow target bone marrow?

Some blood disorders arise from marrow-made blood cells. Marrow receives limited blood supply, so circulating molecules enter poorly. Raising doses to improve entry can increase toxicity.

Rapid marrow-cell division consumes energy, making iron essential. Each red blood cell and progenitor cell in marrow expresses as many as 500,000 transferrin receptors. Marrow’s drugs bind these receptors and enter cells without disrupting their iron-transport function.

CEO Romesh Subramanian said: “So really it’s kind of a Trojan horse. We’re piggybacking onto that transferrin to take [the drug] into the cell.”

Marrow has turned the marrow’s iron demand into a drug-delivery route.

What has transferrin targeting proved?

Transferrin receptors occur throughout the body. The approach already has clinical and regulatory validation.

In March, the FDA approved Denali Therapeutics’ Avlayah for the rare neurologic disorder Hunter syndrome. Avlayah uses the receptor to cross the blood-brain barrier.

Research programs also target neurodegenerative and muscle diseases. At Dyne Therapeutics, where Subramanian previously served as CEO and chief scientific officer, an antigen-binding fragment targets the receptor and is linked to an antisense oligonucleotide payload.

FDA precedent supports the receptor, but not yet Marrow’s marrow selectivity.

What does MAR-101 do?

Marrow’s proprietary engineering favors bone marrow over muscle and the central nervous system. Each transferrin antibody bioconjugate, or TAB, links a receptor-targeting antibody to a drug payload.

For MAR-101, the payload is a small interfering RNA that lowers BCL11a, a protein central to blood-cell development.

Preclinical monkey studies showed marrow target engagement, BCL11a knockdown and potent fetal-hemoglobin induction. Human-cell tests also proved encouraging. Subramanian said the results matched or beat ex vivo approaches to BCL11a.

Fetal hemoglobin could replace malfunctioning adult hemoglobin in both target diseases. Vertex Pharmaceuticals’ Casgevy already addresses BCL11a in both diseases, using CRISPR editing to reduce expression and increase fetal hemoglobin.

MAR-101 seeks the established fetal-hemoglobin effect through targeted RNA knockdown.

How could an injection widen access?

Casgevy and Lyfgenia, a sickle-cell gene therapy from Genetix Biotherapeutics, are one-time treatments. Both require harvesting a patient’s stem cells, engineering them in a laboratory and reinfusing them.

Gene therapy may be curative, but cost and multi-step logistics limit access, particularly outside the United States. Marrow’s goal is a sickle-cell therapy accessible throughout the world.

Marrow aims to develop a self-administered subcutaneous injection that patients could give at home. The company is also developing this formulation to be stable at room temperature.

Subramanian said: “They don’t have to go to the ER, they don’t have to go to other places, they don’t need blood transfusions. That totally changes accessibility, pricing, life quality for them and caregivers.”

Home administration could remove several barriers from the gene-therapy pathway.

Can Marrow manufacture the drug affordably?

A TAB contains three components:

  • Transferrin-receptor-targeting antibody
  • Small-molecule linker
  • Drug payload

Compared with traditional antibodies, this added complexity makes Marrow’s medicines more expensive to manufacture. Subramanian said Marrow optimized its methods for high-yield production and economies of scale.

The company believes it can make MAR-101 a global medicine at price points acceptable to payers worldwide.

Marrow believes manufacturing optimization can offset the added component complexity.

What will the $173 million fund next?

Scion Life Sciences formed and incubated Marrow in 2024. Early 2025, the startup raised a $53 million Series A co-led by Scion and venBio. Marrow withheld the announcement while strengthening intellectual property before its formal launch.

Tuesday’s $120 million Series B was led by OrbiMed. It is more than twice the size of the Series A. The round included all earlier investors, plus:

  • RTW Investments
  • Surveyor Capital, a Citadel company
  • Opaleye
  • NEXTBio Capital
  • Affinity Advisors
  • KKR
  • Spruce Street Capital
  • Columbia Threadneedle Investments

MAR-101 is in late preclinical testing that could support an application seeking FDA authorization to begin a clinical trial. Subramanian declined to give a timeline, saying only: “as soon as feasible.”

Like many platform startups, Marrow indicated openness to collaborating with pharmaceutical companies.

“We are pioneering a targeted in vivo approach to open up this bone marrow space that could address diseases in red blood cells, white blood cells, even cells of the bone potentially,” he said.

“Those are large indications and we don’t take that very lightly. We also see that’s a great opportunity for us to develop many medicines either ourselves or with partners as well.”

The next decisive milestone is FDA authorization for human testing, with no date disclosed.

via businesswire.com (Original)

Share this article:

More from Grace Kim

Grace Kim

Show full bio

Market editor covering companies, deals and strategy in global pharmaceutical industry at PharmInsider.

7 articles

Linked filings

  1. E-3628
  2. K-8919
  3. T-8005
  4. K-7707
  5. V-5496